Open AccessLinezolid induced pancytopenia in a patient of extensively drug-resistant pulmonary tuberculosis: An unusual outcome
Author(s) -
Rajiv Garg,
Ashwini Kumar Mishra,
Ramawadh Singh Kushwaha,
Anubhuti Singh
Publication year - 2016
Publication title -
journal of association of chest physicians
Language(s) - English
Resource type - Journals
eISSN - 2320-9089
pISSN - 2320-8775
DOI - 10.4103/2320-8775.159874
Subject(s) - pancytopenia , medicine , linezolid , tuberculosis , surgery , adverse effect , complication , pediatrics , bone marrow , pathology , vancomycin , biology , bacteria , genetics , staphylococcus aureus
Linezolid (Lnz) is the first oxazolidinones to be developed and introduced in clinical use. Its use is growing by day and day in the treatment of resistant pulmonary tuberculosis (TB). Lnz has been associated with adverse hematological effects, primarily thrombocytopenia. But pancytopenia is a very rare complication. Myelosuppression is a rare and a serious side effect of Lnz. Here, we present a case of extensively drug-resistant pulmonary TB, which was started on Lnz. Patient returned 1-month back with clinical presentation suggestive of pancytopenia which was confirmed on bone marrow aspiration and was attributed to the use of Lnz. Patient improved on stopping the Lnz and adding steroid for a short course. This case report emphasizes the importance of both the use of Lnz for well-defined indications and appropriate hematological monitoring during the course of treatment